Pembrolizumab-induced benign atypical intralymphatic CD30⁺ T-cell proliferation mimicking intravascular lymphoma

J Dermatol. 2022 Feb;49(2):e53-e54. doi: 10.1111/1346-8138.16166. Epub 2021 Sep 27.

Authors

Wei-Kai Hung^{1

2}, Chun-Bing Chen^{1

2

3}, Tseng-Tong Kuo¹, Wei-Ti Chen^{1

2

3

4

5}

Affiliations

¹ Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
² College of Medicine, Chang Gung University, Taoyuan, Taiwan.
³ Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
⁴ College of Medicine, Graduate Institute of Immunology, National Taiwan University, Taipei, Taiwan.
⁵ Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.

PMID: 34580915
DOI: 10.1111/1346-8138.16166

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Cell Proliferation
Humans
Ki-1 Antigen*
Lymphocyte Activation
Lymphoma*

Substances

Antibodies, Monoclonal, Humanized
Ki-1 Antigen
pembrolizumab